← Back to Search

6D-MRI Predictive Imaging for Pancreatic Cancer

N/A

Recruiting

Led By Stephen Pandol, MD

Research Sponsored by Cedars-Sinai Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Pancreatic cancer patients (with resectable or borderline resectable or locally advanced tumors) who will undergo neoadjuvant chemotherapy

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

Study Summary

This trial will test if 6D-MRI can help predict outcomes for pancreatic cancer patients.

Who is the study for?

This trial is for pancreatic cancer patients who can have at least two MRI sessions and are about to start chemotherapy. They must be able to sync a device with Fitbit or use someone else's. It's not for those with severe claustrophobia, previous PDAC treatments, metastatic cancer seen on initial scans, or certain metal implants.Check my eligibility

What is being tested?

The study is testing if a new type of MRI called 6D-MRI can predict how well patients with pancreatic ductal adenocarcinoma will respond to treatment before they begin their chemotherapy regimen.See study design

What are the potential side effects?

Since the intervention involves only MRI scanning, side effects may include discomfort from lying still during the procedure and potential anxiety in the machine. There might also be risks related to contrast agents used during MRIs.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have pancreatic cancer and will receive chemotherapy before surgery.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in functional status from baseline, as measured by the Eastern Cooperative Oncology Group (ECOG) Scale of Performance Status

Change in overall health from baseline, as measured by the Charlson Comorbidity Index (CCI)

Number of participants with R0 resection

+1 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: 6D-MRIExperimental Treatment1 Intervention

Participants will undergo 6D-MRI imaging three times throughout the course of the study: once pre-NAT treatment, once during NAT treatment, and once post-NAT treatment.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Cedars-Sinai Medical CenterLead Sponsor

500 Previous Clinical Trials

164,863 Total Patients Enrolled

Stephen Pandol, MDPrincipal Investigator - Cedars-Sinai Medical Center

Cedars-Sinai Medical Center

1 Previous Clinical Trials

24 Total Patients Enrolled

Media Library

6D-MRI Clinical Trial Eligibility Overview. Trial Name: NCT04700488 — N/A

Pancreatic Cancer Research Study Groups: 6D-MRI

Pancreatic Cancer Clinical Trial 2023: 6D-MRI Highlights & Side Effects. Trial Name: NCT04700488 — N/A

6D-MRI 2023 Treatment Timeline for Medical Study. Trial Name: NCT04700488 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are collaborating in the experiment?

"Correct. The clinicaltrials.gov website affirms that this medical study, which was first listed on May 19th 2022, is currently recruiting participants. 36 volunteers need to be recruited from 1 sites around the country."

Answered by AI

Is this research project open to enrolling new participants?

"Affirmative. According to clinicaltrials.gov, this medical trial was initially unveiled on May 19th 2022 and has since been edited for the last time in October of the same year. 36 individuals are being sought from a single location to take part in this experiment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)

Stephen Pandol, MD 2022. "Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04700488.